
Sign up to save your podcasts
Or


In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
By Vincent Racaniello4.8
20352,035 ratings
In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]

43,923 Listeners

28 Listeners

453 Listeners

38 Listeners

761 Listeners

522 Listeners

169 Listeners

12 Listeners

20 Listeners

4 Listeners

25 Listeners

822 Listeners

6,416 Listeners

236 Listeners

276 Listeners

170 Listeners

953 Listeners

635 Listeners

185 Listeners

4 Listeners

87 Listeners

51 Listeners